Clotting alterations in primary systemic amyloidosis

Haematologica

Volumn 85, Issue 3, 2000, Pages 289-292

  Gamba, Gabriella ^a,b   Montani, Nadia ^a   Anesi, Ernesto ^a   Palladini, Giovanni ^a   Capezzera, Michela ^a   Soldavini, Elena ^a   Merlini, Giampaolo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Amyloidosis; Bleeding tendency; Clotting tests; Hemostasis anomalies

Indexed keywords

AMYLOID; BATROXOBIN; BLOOD CLOTTING FACTOR 10; FIBRINOGEN; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; FEMALE; FIBRIN FORMATION; HEMOSTASIS; HUMAN; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; PROTEIN BINDING; THROMBIN TIME;

ADULT; AGED; AMYLOIDOSIS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; ECCHYMOSIS; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PARAPROTEINEMIAS; PURPURA;

EID: 0034038320     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Falk RH, Comenzo RI, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337:898-909.
2. Yood RA, Skinner M, Rubinow A, Talarico L, Cohen AS. Bleeding manifestations in 100 patients with amyloidosls. JAMA 1983; 249:1322-4.
3. Glaspy JA. Hemostatic abnormalities in multiple myeloma and related disorders. Hematol Oncol Clin N 1992; 6:1301-14.
4. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45-59.
5. Kaiserling E, Krober S. Massive intestinal hemorrhage associated with intestinal amyloidosis. An investigation of underlying pathologic processes. Gen Diagn Pathol 1995; 141:147-54.
6. Hoshino Y, Hatake K, Muroi K, et al. Bleeding tendency caused by the deposit of amyloid substance in the perivascular region. Intern Med 1993; 32:879-81.
7. Gastineau DA, Gertz MA, Daniels TM, Kyle RA, Bowie EJ. Inhibitor of the thrombin time in systemic amyloidosis: a common coagulation abnormality. Blood 1991; 77:2637-40.
8. Furie B, Green E, Furie BC. Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X. N Engl J Med 1977; 297:81-5.
9. Greipp PR, Kyle RA, Bowie EJ. Factor-X deficiency in amyloidosis: a critical review. Am J Hematol 1981; 11:443-50.
10. Furie B, Voo L, McAdam KP, Furie BC. Mechanism of factor X deficiency in systemic amyloidosis. N Engl J Med 1981; 304:827-30.
11. Skinner M, Talarico L, Cohen AS, St John A. The calcium dependent interaction of blood clotting factors with primary amyloid fibrils. In: Glenner GG, Costa PP, De Freitas AF, eds. Amyloid and amyloidosis. #497 of International Congress Series. Amsterdam: Excerpta Medica; 1980. p. 361-5.
12. McPherson RA, Onstad JW, Ugoretz RG, Wolf PL. Coagulopathy in amyloidosis: combined deficiency of factors IX and X. AmJ Hematol 1977; 3:225-35.
13. Gatel A, Cacoub P, Piette JC. AL amyloidosis combined with acquired factor V deficiency. Ann Intern Med 1998; 128:604-5.
14. Khoory MS, Nesheim ME, Bowie EJ, Mann KG. Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder. J Clin Invest 1980; 65:666-74.
15. Perfetti V, Garini P, Colli Vignarelli M, Marinone MG, Zorzoli I, Merlini G. Diagnostic approach to and follow-up of difficult cases of AL amyloidosis. Haematologica 1995; 80:409-15.
16. Joist JH. Haemostatic abnormalities in liver diseases. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Haemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: JB Lippincott Company; 1994. p. 906-20.
17. Marcatti M, Mauri S, Tresoldi M, et al. Unusual bleeding manifestations in a case of primary amyloidosis with factorX deficiency but elevations of in vivo markers of thrombin formation and activity. Thromb Res 1995; 80: 333-7.
18. Gamba G, Montani N, Anesi E, Zorzoli I, Lorenzutti F, Merlini G. Alteration of the thrombin inactivation by antithrombin III may contribute to the abnormal haemostasis in AL amyloidosis. In: Kyle RA and Gertz MA, eds. Amyloid and Amyloidosis. New York: The Parthenon Publishing Group; 1999. p. 145-7.
19. Nishimoto N, Shima Y, Yoshizaki K, Kishimoto T. Myeloma biology and therapy. Present status and future developments. Hematol Oncol Clin N 1997; 11:159-72.
20. Bellotti V, Gamba G, Merlini G, et al. Study of three patients with monoclonal gammopathies and 'lupus-like' anticoagulants. Br J Haematol 1989; 73:221-7.
21. Carlson HC, Breen JF. Amyloidosis and plasma cell dyscrasias: gastrointestinal involvement. Semin Roentgenol 1986; 21:128-38.
22. Gertz MA, Kyle RA. Hepatic amyloidosis (primary AL immunoglobulin light chain): the natural history in 80 patients. Am J Med 1988; 85:73-80.
23. Husby G, Stenstad T, Magnus JH, Sletten K, Nordvag BY, Marhaug G. Interaction between circulating amyloid fibril protein precursors and extracellular tissue matrix components in the pathogenesis of systemic amyloidosis. Clin Immunol Immunop 1994; 70:2-9.
24. Eriksson S, Janciauskiene S, Merlini G. The putative role of alpha-1-antitrypsin in the disaggregation of amyloid lambda fibrils. J Intern Med 1995; 237:143-9.
25. Liebman HA, Carfagano MK, Weitz IC, et al. Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase. Am J Pathol 1992; 98:534-41.
26. Meyer K, Williams EC. Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis. Am J Med 1985; 79:394-6.
27. Takahashi H, Koike T, Yoshida N, et al. Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma. Am J Hematol 1986; 23:153-66.